Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data.

The article focuses on Immune checkpoint inhibitors that have been increasingly used as a monotherapy or in combination with chemotherapy in the frontline setting for various cancers. Topics include examines despite significant clinical benefits, ICIs are associated with a unique spectrum of adverse effects termed immune-related adverse events.